Who
Leah R. Neufeld
Chief People Officer
Company insider
Files Form 4 as: Chief People Officer, Immuneering.
In numbers
- Trades disclosed
- 21
- Buys
- 4
- Sells
- 0
- Bought
- $40K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Oct 2022
- Last trade
- 13 Mar 2026
- Last filed
- 17 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Mar 2026filed 17 Mar 2026 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code A | $16K3,628 at $4.29 | filing |
| 13 Mar 2026filed 17 Mar 2026 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code A | $16K3,628 at $4.29 | filing |
| 3 Feb 2026filed 5 Feb 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $11K2,626 at $4.15 | filing |
| 13 Jan 2026filed 15 Jan 2026 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $11K2,626 at $4.15 | filing |
| 1 Oct 2025filed 2 Oct 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $5,104800 at $6.38 | filing |
| 15 Sep 2025filed 17 Sep 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code A | $17K11,815 at $1.43 | filing |
| 2 Jul 2025filed 7 Jul 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $2,499700 at $3.57 | filing |
| 5 Feb 2025filed 7 Feb 2025 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code D | —88,600 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,600 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code D | —105,000 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code D | —60,500 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,500 at $0.00 | filing |
| 20 Mar 2024filed 21 Mar 2024 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $11K3,818 at $2.88 | filing |
| 15 Mar 2024filed 21 Mar 2024 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code A | $10K6,211 at $1.62 | filing |
| 8 Feb 2024filed 9 Feb 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,500 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.